BidaskClub upgraded shares of Corindus Vascular Robotics Inc (NYSEMKT:CVRS) from a sell rating to a hold rating in a research note issued to investors on Friday morning.
Other analysts have also issued reports about the company. B. Riley restated a buy rating and issued a $3.00 target price on shares of Corindus Vascular Robotics in a research note on Monday, May 15th. ValuEngine upgraded Corindus Vascular Robotics from a sell rating to a hold rating in a research note on Thursday, June 22nd. Zacks Investment Research lowered Corindus Vascular Robotics from a hold rating to a sell rating in a research note on Tuesday, May 16th. Finally, Cowen and Company set a $3.00 target price on Corindus Vascular Robotics and gave the company a buy rating in a research note on Wednesday, August 9th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Corindus Vascular Robotics presently has an average rating of Buy and a consensus target price of $2.58.
Shares of Corindus Vascular Robotics (NYSEMKT CVRS) opened at 1.78 on Friday. The stock has a 50 day moving average of $1.70 and a 200 day moving average of $1.34. The firm’s market cap is $333.39 million. Corindus Vascular Robotics has a 1-year low of $0.40 and a 1-year high of $2.25.
Corindus Vascular Robotics (NYSEMKT:CVRS) last announced its earnings results on Tuesday, August 8th. The medical equipment provider reported ($0.04) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. Corindus Vascular Robotics had a negative return on equity of 181.63% and a negative net margin of 1,272.20%. The company had revenue of $2.26 million during the quarter, compared to analyst estimates of $3.10 million. Equities research analysts anticipate that Corindus Vascular Robotics will post ($0.21) earnings per share for the current fiscal year.
WARNING: This report was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://stocknewstimes.com/2017/08/28/corindus-vascular-robotics-inc-cvrs-lifted-to-hold-at-bidaskclub.html.
Hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its stake in shares of Corindus Vascular Robotics by 6.3% in the first quarter. Bank of New York Mellon Corp now owns 163,012 shares of the medical equipment provider’s stock worth $214,000 after buying an additional 9,684 shares during the period. Rhumbline Advisers raised its stake in shares of Corindus Vascular Robotics by 67.6% in the second quarter. Rhumbline Advisers now owns 80,868 shares of the medical equipment provider’s stock worth $150,000 after buying an additional 32,608 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Corindus Vascular Robotics by 147.8% in the second quarter. Goldman Sachs Group Inc. now owns 58,824 shares of the medical equipment provider’s stock worth $109,000 after buying an additional 35,086 shares during the period. California State Teachers Retirement System raised its stake in shares of Corindus Vascular Robotics by 34.4% in the second quarter. California State Teachers Retirement System now owns 148,558 shares of the medical equipment provider’s stock worth $276,000 after buying an additional 38,000 shares during the period. Finally, New York State Common Retirement Fund boosted its position in Corindus Vascular Robotics by 334.6% in the second quarter. New York State Common Retirement Fund now owns 89,100 shares of the medical equipment provider’s stock valued at $166,000 after buying an additional 68,599 shares in the last quarter.
About Corindus Vascular Robotics
Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.
Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
